Sorafenib-resistant HCC cells demonstrate diminished susceptibility to sorafenib’s growth inhibitory and apoptotic effects, accompanied by heightened activation of AKT and its downstream effectors. Here, AKT1 is linked to hepatocellular carcinoma.